Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 11, 2011, Pages 835-843

  Tibolla, G ^a,c   Norata, G D ^a,b   Artali, R ^a   Meneghetti, F ^a   Catapano, A L ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b Ospedale Bassini   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

LDL receptor; PCSK9; Plasma LDL cholesterol; Statins

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ANIMAL; BLOOD; CHEMISTRY; GENETICS; HUMAN; HYPERCHOLESTEROLEMIA; METABOLISM; MUTATION; PHYSIOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; MUTATION; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053961826     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.06.002     Document Type: Review

References (76)

1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106(25):3143-3421. Third Report of the National Cholesterol Education Program (NCEP).
2. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207.
3. Rao D.C., Laskarzewski P.M., Morrison J.A., Khoury P., Kelly K., Wette R., et al. The Cincinnati lipid research clinic family study: cultural and biological determinants of lipids and lipoprotein concentrations. Am J Hum Genet 1982, 34(6):888-903.
4. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34(2):154-156.
5. Benjannet S., Rhainds D., Essalmani R., Mayne J., Wickham L., Jin W., et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004, 279(47):48865-48875.
6. Cunningham D., Danley D.E., Geoghegan K.F., Griffor M.C., Hawkins J.L., Subashi T.A., et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007, 14(5):413-419.
7. Park S.W., Moon Y.A., Horton J.D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004, 279(48):50630-50638.
8. Horton J.D., Shah N.A., Warrington J.A., Anderson N.N., Park S.W., Brown M.S., et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 2003, 100(21):12027-12032.
9. Maxwell K.N., Soccio R.E., Duncan E.M., Sehayek E., Breslow J.L. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 2003, 44(11):2109-2119.
10. Jeong H.J., Lee H.S., Kim K.S., Kim Y.K., Yoon D., Park S.W. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 2008, 49(2):399-409.
11. Dubuc G., Chamberland A., Wassef H., Davignon J., Seidah N.G., Bernier L., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24(8):1454-1459.
12. Browning J.D., Horton J.D. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010, 51(11):3359-3363.
13. Persson L., Cao G., Stahle L., Sjoberg B., Troutt J.S., Konrad R.J., et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 2010, 30(12):2666-2672.
14. Persson L., Galman C., Angelin B., Rudling M. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology 2009, 150(3):1140-1146.
15. Langhi C., Le May C., Kourimate S., Caron S., Staels B., Krempf M., et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett 2008, 582(6):949-955.
16. Cameron J., Ranheim T., Kulseth M.A., Leren T.P., Berge K.E. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008, 201(2):266-273.
17. Feingold K.R., Moser A.H., Shigenaga J.K., Patzek S.M., Grunfeld C. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 2008, 374(2):341-344.
18. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100(3):928-933.
19. Essalmani R., Susan-Resiga D., Chamberland A., Abifadel M., Cremers J.W., Boileau C., et al. In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem 2011 Feb 11, 286(6):4257-4263.
20. Qian Y.W., Schmidt R.J., Zhang Y., Chu S., Lin A., Wang H., et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007, 48(7):1488-1498.
21. Nassoury N., Blasiole D.A., Tebon Oler A., Benjannet S., Hamelin J., Poupon V., et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 2007, 8(6):718-732.
22. Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007, 282(25):18602-18612.
23. Yamamoto T., Lu C., Ryan R.O. A two step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem 2011 Feb 18, 286(7):5464-5470.
24. Maxwell K.N., Fisher E.A., Breslow J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A 2005, 102(6):2069-2074.
25. Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J., Nassoury N., et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008, 283(4):2363-2372.
26. Liu M., Wu G., Baysarowich J., Kavana M., Addona G.H., Bierilo K.K., et al. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J Lipid Res 2010, 51(9):2611-2618.
27. Luo Y., Warren L., Xia D., Jensen H., Sand T., Petras S., et al. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res 2009, 50(8):1581-1588.
28. Mayer G., Poirier S., Seidah N.G. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem 2008, 283(46):31791-31801.
29. Blesa S., Vernia S., Garcia-Garcia A.B., Martinez-Hervas S., Ivorra C., Gonzalez-Albert V., et al. A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia. J Clin Endocrinol Metab 2008, 93(9):3577-3583.
30. Shioji K., Mannami T., Kokubo Y., Inamoto N., Takagi S., Goto Y., et al. Genetic variants in PCSK9 affect the cholesterol level in Japanese. J Hum Genet 2004, 49(2):109-114.
31. Miyake Y., Kimura R., Kokubo Y., Okayama A., Tomoike H., Yamamura T., et al. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008, 196(1):29-36.
32. Fasano T., Cefalu A.B., Di Leo E., Noto D., Pollaccia D., Bocchi L., et al. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 2007, 27(3):677-681.
33. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., Kinch L., Grishin N.V., Horton J.D., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79(3):514-523.
34. Berge K.E., Ose L., Leren T.P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 2006, 26(5):1094-1100.
35. Fasano T., Sun X.M., Patel D.D., Soutar A.K. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis 2009, 203(1):166-171.
36. Homer V.M., Marais A.D., Charlton F., Laurie A.D., Hurndell N., Scott R., et al. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 2008, 196(2):659-666.
37. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37(2):161-165.
38. Cameron J., Holla O.L., Laerdahl J.K., Kulseth M.A., Ranheim T., Rognes T., et al. Characterization of novel mutations in the catalytic domain of the PCSK9 gene. J Intern Med 2008, 263(4):420-431.
39. Allard D., Amsellem S., Abifadel M., Trillard M., Devillers M., Luc G., et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005, 26(5):497.
40. Kotowski I.K., Pertsemlidis A., Luke A., Cooper R.S., Vega G.L., Cohen J.C., et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006, 78(3):410-422.
41. Bourbon M., Alves A.C., Medeiros A.M., Silva S., Soutar A.K. Familial hypercholesterolaemia in Portugal. Atherosclerosis 2008, 196(2):633-642.
42. Dubuc G., Tremblay M., Pare G., Jacques H., Hamelin J., Benjannet S., et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010, 51(1):140-149.
43. Cameron J., Holla O.L., Laerdahl J.K., Kulseth M.A., Berge K.E., Leren T.P. Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage. Atherosclerosis 2009, 203(1):161-165.
44. Pisciotta L., Priore Oliva C., Cefalu A.B., Noto D., Bellocchio A., Fresa R., et al. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis 2006, 186(2):433-440.
45. Timms K.M., Wagner S., Samuels M.E., Forbey K., Goldfine H., Jammulapati S., et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004, 114(4):349-353.
46. Leren T.P. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004, 65(5):419-422.
47. Naoumova R.P., Tosi I., Patel D., Neuwirth C., Horswell S.D., Marais A.D., et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 2005, 25(12):2654-2660.
48. Norata G.D., Garlaschelli K., Grigore L., Raselli S., Tramontana S., Meneghetti F., et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010, 208(1):177-182.
49. Hooper A.J., Marais A.D., Tanyanyiwa D.M., Burnett J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007, 193(2):445-448.
50. Cameron J., Holla O.L., Ranheim T., Kulseth M.A., Berge K.E., Leren T.P. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006, 15(9):1551-1558.
51. Cariou B., Ouguerram K., Zair Y., Guerois R., Langhi C., Kourimate S., et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009, 29(12):2191-2197.
52. Lagace T.A., Curtis D.E., Garuti R., McNutt M.C., Park S.W., Prather H.B., et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006, 116(11):2995-3005.
53. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94(7):2537-2543.
54. Baass A., Dubuc G., Tremblay M., Delvin E.E., O'Loughlin J., Levy E., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55(9):1637-1645.
55. Cui Q., Ju X., Yang T., Zhang M., Tang W., Chen Q., et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010, 213(2):632-636.
56. Alborn W.E., Cao G., Careskey H.E., Qian Y.W., Subramaniam D.R., Davies J., et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007, 53(10):1814-1819.
57. Welder G., Zineh I., Pacanowski M.A., Troutt J.S., Cao G., Konrad R.J. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010, 51(9):2714-2721.
58. Ouguerram K., Chetiveaux M., Zair Y., Costet P., Abifadel M., Varret M., et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 2004, 24(8):1448-1453.
59. Lambert G., Jarnoux A.L., Pineau T., Pape O., Chetiveaux M., Laboisse C., et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 2006, 147(10):4985-4995.
60. Lalanne F., Lambert G., Amar M.J., Chetiveaux M., Zair Y., Jarnoux A.L., et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res 2005, 46(6):1312-1319.
61. Chan D.C., Lambert G., Barrett P.H., Rye K.A., Ooi E.M., Watts G.F. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?. Clin Chem 2009, 55(11):2049-2052.
62. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008, 49(2):394-398.
63. Troutt J.S., Alborn W.E., Cao G., Konrad R.J. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res 2010, 51(2):345-351.
64. Lambert G., Ancellin N., Charlton F., Comas D., Pilot J., Keech A., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54(6):1038-1045.
65. Nilsson L.M., Abrahamsson A., Sahlin S., Gustafsson U., Angelin B., Parini P., et al. Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem Biophys Res Commun 2007, 357(3):707-711.
66. Rashid S., Curtis D.E., Garuti R., Anderson N.N., Bashmakov Y., Ho Y.K., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005, 102(15):5374-5379.
67. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354(12):1264-1272.
68. Chan J.C., Piper D.E., Cao Q., Liu D., King C., Wang W., et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009, 106(24):9820-9825.
69. Graham M.J., Lemonidis K.M., Whipple C.P., Subramaniam A., Monia B.P., Crooke S.T., et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007, 48(4):763-767.
70. Frank-Kamenetsky M., Grefhorst A., Anderson N.N., Racie T.S., Bramlage B., Akinc A., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008, 105(33):11915-11920.
71. Gupta N., Fisker N., Asselin M.C., Lindholm M., Rosenbohm C., Orum H., et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 2010, 5(5):e10682.
72. Ni Y.G., Di Marco S., Condra J.H., Peterson L.B., Wang W., Wang F., et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9)-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces free circulating PCSK9 and LDL-cholesterol. J Lipid Res 2011, 52(1):78-86.
73. Ni Y.G., Di Marco S., Condra J.H., Peterson L.B., Wang W., Wang F., et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res 2011, 52(1):78-86.
74. Seidah N.G., Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med 2007, 85(7):685-696.
75. Grefhorst A., McNutt M.C., Lagace T.A., Horton J.D. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res 2008, 49(6):1303-1311.
76. Hedrick J.A. Targeting PCSK9 for the treatment of hypercholesterolemia. Curr Opin Investig Drugs 2009, 10(9):938-946.